A Case of Glutaric Aciduria Type I with Macrocephaly.
- Author:
Woo Jong SHIN
1
;
Yeo Ok MOON
;
Hye Ran YOON
;
Eun Sil DONG
;
Young Min AHN
Author Information
1. Department of Pediatrics, Kangnam General Hospital Public Co, Korea. ymahn@kangnamhosp.or.kr
- Publication Type:Case Report
- Keywords:
Glutaric aciduria type 1;
Glutaryl-CoA dehydrogenase;
Macrocephaly;
Acute encephalopathy;
Frontotemporal atrophy;
Lysine free milk;
Carnitine
- MeSH:
Atrophy;
Brain;
Carnitine;
Caudate Nucleus;
Diagnosis, Differential;
Fibroblasts;
Gastroenteritis;
Glutaryl-CoA Dehydrogenase;
Humans;
Hydroxylysine;
Immunization;
Infant;
Lysine;
Macrocephaly*;
Magnetic Resonance Imaging;
Male;
Metabolism;
Milk;
Muscle Hypotonia;
Neurologic Manifestations;
Parturition;
Putamen;
Riboflavin;
Tandem Mass Spectrometry;
Tryptophan
- From:Journal of the Korean Pediatric Society
2003;46(3):295-301
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Glutaric aciduria type 1(GA1) is an autosomal recessive disorder of the lysine, hydroxylysine and tryptophan metabolism caused by the deficiency of mitochondrial glutaryl-CoA dehydrogenase. This disease is characterized by macrocephaly at birth or shortly after birth and various neurologic symptoms. Between the first weeks and the 4-5th year of life, intercurrent illness such as viral infections, gastroenteritis, or even routine immunizations can trigger acute encephalopathy, causing injury to caudate nucleus and putamen. But intellectual functions are well preserved until late in the disease course. We report a one-month-old male infant with macrocephaly and hypotonia. In brain MRI, there was frontotemporal atrophy(widening of sylvian cistern). In metabolic investigation, there were high glutarylcarnitine level in tandem mass spectrometry and high glutarate in urine organic acid analysis, GA1 was confirmed by absent glutaryl-CoA dehydrogenase activity in fibroblast culture. He was managed with lysine free milk and carnitine and riboflavin. He developed well without a metabolic crisis. If there is macrocephaly in an infant with neuroradiologic sign of frontotemporal atrophy, GA1 should have a high priority in the differential diagnosis. Because current therapy can prevent brain degeneration in more than 90% of affected infants who are treated prospectively, recognition of this disorder before the brain has been injured is essential for treatment.
